filgotinib
NHS in Scotland makes rheumatoid arthritis drug available
September 14, 2021Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis
The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active …
FDA turns down Gilead’s JAK inhibitor filgotinib in rheumatoid arthritis, endangering 2020 approval hopes
August 20, 2020Research and Development, Sales and Marketing FDA, Gilead, filgotinib
Gilead’s JAK inhibitor filgotinib has been unexpectedly knocked back by the FDA as a therapy to treat moderately to severely …
Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome
October 28, 2019Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma
Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …
Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal
September 7, 2018Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma
Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …
Gilead steps in to rescue Galapagos RA drug
December 18, 2015Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis
Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …
